Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
Myriad Genetics (NASDAQ: MYGN) achieved significant recognition as their MyRisk® Hereditary Cancer Test with RiskScore® study was named among the top 10 advances in genomic medicine by the American Journal of Human Genetics. The study, selected by the National Human Genome Research Institute's Genomic Medicine Working Group, validated RiskScore's effectiveness using data from over 130,000 women.
The research demonstrated that RiskScore, which combines a polygenic risk score (PRS) for all ancestries with the Tyrer-Cuzick model, is twice as accurate in predicting breast cancer risk compared to the Tyrer-Cuzick model alone. Notably, Myriad was among the first commercial laboratories to introduce a multi-ancestry breast-cancer PRS, advancing health equity through more inclusive genetic insights.
Myriad Genetics (NASDAQ: MYGN) ha ottenuto un riconoscimento significativo poiché il loro studio MyRisk® Hereditary Cancer Test with RiskScore® è stato selezionato tra i 10 migliori progressi nella medicina genomiica dalla American Journal of Human Genetics. Lo studio, scelto dal Grupo di Lavoro di Medicina Genomica del National Human Genome Research Institute, ha convalidato l'efficacia di RiskScore utilizzando dati di oltre 130.000 donne.
La ricerca ha dimostrato che RiskScore, che combina un punteggio di rischio poligenico (PRS) per tutte le origini con il modello Tyrer-Cuzick, è due volte più preciso nella previsione del rischio di cancro al seno rispetto al solo modello Tyrer-Cuzick. È importante notare che Myriad è stata tra i primi laboratori commerciali a introdurre un PRS per il cancro al seno a più ancestrie, promuovendo l'equità nella salute attraverso intuizioni genetiche più inclusive.
Myriad Genetics (NASDAQ: MYGN) logró un reconocimiento significativo ya que su estudio MyRisk® Hereditary Cancer Test with RiskScore® fue nombrado entre los 10 principales avances en medicina genómica por el American Journal of Human Genetics. El estudio, seleccionado por el Grupo de Trabajo en Medicina Genómica del National Human Genome Research Institute, validó la efectividad de RiskScore utilizando datos de más de 130,000 mujeres.
La investigación demostró que RiskScore, que combina un puntaje de riesgo poligénico (PRS) para todas las ascendencias con el modelo Tyrer-Cuzick, es dos veces más preciso en predecir el riesgo de cáncer de mama en comparación con el modelo Tyrer-Cuzick por sí solo. Cabe destacar que Myriad fue uno de los primeros laboratorios comerciales en introducir un PRS para el cáncer de mama con múltiples ascendencias, promoviendo la equidad en salud a través de conocimientos genéticos más inclusivos.
미래 유전학 (NASDAQ: MYGN)은 그들의 MyRisk® 유전성 암 검사와 RiskScore® 연구가 미국 인간 유전학 저널에 의해 유전 의학의 10대 발전 중 하나로 선정된 중요한 인정을 받았습니다. 이 연구는 국가 인간 게놈 연구소의 유전 의학 워킹 그룹에 의해 선택되었으며, 130,000명 이상의 여성 데이터를 사용하여 RiskScore의 유효성을 검증했습니다.
연구는 모든 조상에 대한 다중 유전적 위험 점수(PRS)와 Tyrer-Cuzick 모델을 결합한 RiskScore가 Tyrer-Cuzick 모델 단독에 비해 유방암 위험 예측에서 두 배 더 정확하다는 것을 보여주었습니다. 특히, Myriad는 다양한 조상의 유방암 PRS를 도입한 최초의 상업 실험실 중 하나로, 보다 포괄적인 유전적 통찰력을 통해 건강 형평성을 증진했습니다.
Myriad Genetics (NASDAQ: MYGN) a obtenu une reconnaissance significative car son étude MyRisk® Hereditary Cancer Test with RiskScore® a été nommée parmi les 10 grandes avancées en médecine génomique par l'American Journal of Human Genetics. L'étude, sélectionnée par le Groupe de travail sur la médecine génomique de l'Institut national de recherche sur le génome humain, a validé l'efficacité de RiskScore en utilisant les données de plus de 130 000 femmes.
La recherche a démontré que RiskScore, qui combine un score de risque polygénique (PRS) pour toutes les origines avec le modèle Tyrer-Cuzick, est deux fois plus précis pour prédire le risque de cancer du sein par rapport au modèle Tyrer-Cuzick seul. Il est à noter que Myriad a été l'un des premiers laboratoires commerciaux à introduire un PRS pour le cancer du sein à multiples origines, promouvant l'équité en santé grâce à des insights génétiques plus inclusifs.
Myriad Genetics (NASDAQ: MYGN) hat bedeutende Anerkennung erhalten, da ihre Studie MyRisk® Hereditary Cancer Test with RiskScore® von der American Journal of Human Genetics als einer der 10 wichtigsten Fortschritte in der genomischen Medizin benannt wurde. Die Studie, die vom Genomischen Medizin Arbeitsgruppe des National Human Genome Research Institute ausgewählt wurde, validierte die Effektivität von RiskScore anhand von Daten von über 130.000 Frauen.
Die Forschung zeigte, dass RiskScore, das einen polygenen Risikowert (PRS) für alle Abstammungen mit dem Tyrer-Cuzick-Modell kombiniert, doppelt so genau ist bei der Vorhersage des Risikos von Brustkrebs im Vergleich zum Tyrer-Cuzick-Modell allein. Hervorzuheben ist, dass Myriad eines der ersten kommerziellen Laboratorien war, das einen PRS für Brustkrebs mit mehreren Abstammungen eingeführt hat, um die Chancengleichheit im Gesundheitswesen durch umfassendere genetische Erkenntnisse voranzutreiben.
- None.
- None.
Study Demonstrates RiskScore as a More Accurate Predictor of Breast Cancer Risk, Doubling Accuracy Compared to the Tyrer-Cuzick Model
SALT LAKE CITY, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic testing and precision medicine, announced that a MyRisk® Hereditary Cancer Test with RiskScore® study has been named in the American Journal of Human Genetics as one of its top 10 significant advances in genomic medicine. The study was selected by the Genomic Medicine Working Group at the National Human Genome Research Institute.
The study by Mabey et al., “Validation of a clinical breast cancer risk assessment tool combining a polygenic score for all ancestries with traditional risk factors,” presented a longitudinal clinical validation of MyRisk with RiskScore using data from more than 130,000 women referred for hereditary cancer genetic testing.
RiskScore integrates a polygenic risk score (PRS) for all ancestries with the widely used Tyrer-Cuzick model. The study demonstrated that Myriad’s PRS is a more accurate predictor of breast cancer risk than Tyrer-Cuzick alone. In fact, RiskScore delivered two times the ability to predict breast cancer risk than the Tyrer-Cuzick model. Additionally, Myriad was one of the first commercial laboratories to market with a multi-ancestry breast-cancer PRS, driven by its mission to advance health equity and deliver more inclusive genetic insights.
“We are honored by this recognition, which underscores the clinical significance of the validation research from the study and predictive accuracy of RiskScore,” said Dale Muzzey, PhD, Chief Scientific Officer at Myriad Genetics. "MyRisk with RiskScore can assist both clinicians and patients in making informed, proactive medical management decisions to help prevent breast cancer or detect it early. The accuracy of RiskScore across all ancestries emphasizes Myriad’s commitment and contribution to health equity.”
"We hope that the selection of our paper as a major advance will continue to drive the adoption of RiskScore by providers and guideline societies," continued Muzzey.
About MyRisk® Hereditary Cancer Test with RiskScore®
MyRisk Hereditary Cancer Test with RiskScore evaluates 48 genes associated with hereditary cancer risk to identify genetic changes associated with an increased cancer risk for 11 different cancers. When combined with family history and other clinical factors such as breast density, MyRisk with RiskScore provides eligible patients with a five-year and remaining lifetime breast cancer risk assessment individualized to them.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including that MyRisk with RiskScore being featured as a top innovation in genomic medicine reinforces the need for more wide-scale clinical implementation of MyRisk with RiskScore, as this data is likely to have implications for healthcare systems and practice guidelines, and MyRisk with RiskScore can assist both clinicians and patients in making informed, proactive medical management decisions to help prevent breast cancer or detect it early. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Glenn Farrell
(385) 318-3718
PR@myriad.com
FAQ
What makes Myriad Genetics' RiskScore more accurate than the Tyrer-Cuzick model for breast cancer prediction?
How many women were included in the MYGN RiskScore validation study?
What distinguishes Myriad's RiskScore from other breast cancer risk assessment tools?
What recognition did Myriad Genetics' RiskScore study receive in December 2024?
How does MYGN's MyRisk with RiskScore benefit healthcare providers and patients?
